Appendix 4E and Preliminary Final Report

Key points

• Loss from ordinary activities after tax up 80.3% to $18,809,512
• Net liabilities at $7,722,773 as at 30 June 2026
• Impairment expense of $10,272,808 for CLTX intellectual property

Full summary

Chimeric Therapeutics Ltd reported a loss for the year ended 30 June 2026 of $18,809,512, up 80.3% from the previous year, largely due to impairment expenses totaling $10,272,808 for the CLTX intellectual property and $519,716 for the CDH-17 intellectual property. The company's net liabilities stood at $7,722,773 as of 30 June 2026, with cash reserves decreasing to $800,145 from $5,757,474 the previous year. The company reported nil revenue for the year.

Guidance

Loss from ordinary activities after tax up 80.3% to $18,809,512

Outlook

The company expects the Audited financial statements to be released by the end of September 2026.